<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40904901</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>15</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>15</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1178-6973</ISSN><JournalIssue CitedMedium="Print"><Volume>18</Volume><PubDate><Year>2025</Year></PubDate></JournalIssue><Title>Infection and drug resistance</Title><ISOAbbreviation>Infect Drug Resist</ISOAbbreviation></Journal><ArticleTitle>Palivizumab for Severe Respiratory Syncytial Virus Infection in Immunocompetent Adults: A Case Series.</ArticleTitle><Pagination><StartPage>4455</StartPage><EndPage>4460</EndPage><MedlinePgn>4455-4460</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2147/IDR.S528785</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Respiratory syncytial virus (RSV) is a significant cause of lower respiratory tract infections in adults, particularly the elderly, and can lead to severe outcomes, including respiratory failure. Current treatment options for RSV in immunocompetent adults are limited to supportive care.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">This case series aims to describe the clinical course and outcomes of two immunocompetent adults with severe RSV infection treated with Palivizumab, a monoclonal antibody against RSV.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We report two cases: a 92-year-old female with a history of hypertension and a previous meningioma resection, and a 42-year-old female with no significant past medical history. Both presented with severe respiratory symptoms, were diagnosed with RSV infection via PCR, and received a single dose of intramuscular Palivizumab (approximately 12-13 mg/kg) after initial clinical deterioration despite supportive care and empiric antibiotic therapy.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Following Palivizumab administration, both patients exhibited clinical improvement, including resolution of fever and improvement in oxygenation and radiographic findings. Both patients were discharged in stable condition without the need for supplemental oxygen.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">These cases suggest that Palivizumab may be a potential therapeutic option for severe RSV infection in immunocompetent adults. Further research, including randomized controlled trials, is needed to confirm these preliminary findings and establish optimal dosing and treatment protocols.</AbstractText><CopyrightInformation>&#xa9; 2025 Zhong et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhong</LastName><ForeName>Jun-Yu</ForeName><Initials>JY</Initials><Identifier Source="ORCID">0009-0006-9244-4881</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yeh</LastName><ForeName>Ting-Kuang</ForeName><Initials>TK</Initials><Identifier Source="ORCID">0000-0001-5540-4780</Identifier><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Genomic Center for Infectious Diseases, Taichung Veterans General Hospital, Taichung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Hsien-Po</ForeName><Initials>HP</Initials><Identifier Source="ORCID">0009-0005-8697-1047</Identifier><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Genomic Center for Infectious Diseases, Taichung Veterans General Hospital, Taichung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ho</LastName><ForeName>Chun-Mei</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Po-Yu</ForeName><Initials>PY</Initials><Identifier Source="ORCID">0000-0001-8006-4917</Identifier><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Rong Hsing Research Center for Translational Medicine, National Chung Hsing University, Taichung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fu</LastName><ForeName>Yun-Ching</ForeName><Initials>YC</Initials><AffiliationInfo><Affiliation>Department of Pediatric Cardiology, Taichung Veterans General Hospital, Taichung, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Children's Medical Center, Taichung Veterans General Hospital, Taichung, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, School of Medicine, National Chung-Hsing University, Taichung, Taiwan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Infect Drug Resist</MedlineTA><NlmUniqueID>101550216</NlmUniqueID><ISSNLinking>1178-6973</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">immunocompetent adults</Keyword><Keyword MajorTopicYN="N">palivizumab</Keyword><Keyword MajorTopicYN="N">respiratory syncytial virus</Keyword></KeywordList><CoiStatement>The authors declare that they have no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>4</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>4</Day><Hour>6</Hour><Minute>38</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>4</Day><Hour>6</Hour><Minute>37</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>4</Day><Hour>4</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>8</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40904901</ArticleId><ArticleId IdType="pmc">PMC12402706</ArticleId><ArticleId IdType="doi">10.2147/IDR.S528785</ArticleId><ArticleId IdType="pii">528785</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mokrani D, Le Hingrat Q, Thy M, et al. Clinical characteristics and outcomes of respiratory syncytial virus-associated ARF in immunocompetent patients: a seven-year experience at a tertiary hospital in France. <i>J Infect</i>. 2024;89(1):106180. doi: 10.1016/j.jinf.2024.106180
</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2024.106180</ArticleId><ArticleId IdType="pubmed">38759759</ArticleId></ArticleIdList></Reference><Reference><Citation>Nam HH, Ison MG. Respiratory syncytial virus infection in adults. <i>BMJ</i>. 2019;366:l5021. doi: 10.1136/bmj.l5021
</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.l5021</ArticleId><ArticleId IdType="pubmed">31506273</ArticleId></ArticleIdList></Reference><Reference><Citation>Noor A, Krilov LR. A historical perspective on respiratory syncytial virus prevention: a journey spanning over half a century from the setback of an inactive vaccine candidate to the success of passive immunization strategy. <i>J Pediatric Infect Dis Soc</i>. 2024;13(Supplement_2):S103&#x2013;S109. doi: 10.1093/jpids/piae027
</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jpids/piae027</ArticleId><ArticleId IdType="pubmed">38577737</ArticleId></ArticleIdList></Reference><Reference><Citation>Boeckh M, Berrey MM, Bowden RA, Crawford SW, Balsley J, Corey L. Phase 1 evaluation of the respiratory syncytial virus-specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplants. <i>J Infect Dis</i>. 2001;184(3):350&#x2013;354. doi: 10.1086/322043
</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/322043</ArticleId><ArticleId IdType="pubmed">11443562</ArticleId></ArticleIdList></Reference><Reference><Citation>McCoy D, Wong E, Kuyumjian AG, Wynd MA, Sebti R, Munk GB. Treatment of respiratory syncytial virus infection in adult patients with hematologic malignancies based on an institution-specific guideline. <i>Transpl Infect Dis</i>. 2011;13(2):117&#x2013;121. doi: 10.1111/j.1399-3062.2010.00561.x
</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1399-3062.2010.00561.x</ArticleId><ArticleId IdType="pubmed">20804534</ArticleId></ArticleIdList></Reference><Reference><Citation>Khanna N, Widmer AF, Decker M, et al. Respiratory syncytial virus infection in patients with hematological diseases: single-center study and review of the literature. <i>Clin Infect Dis</i>. 2008;46(3):402&#x2013;412. doi: 10.1086/525263
</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/525263</ArticleId><ArticleId IdType="pubmed">18181739</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsitsikas DA, Oakervee H, Cavenagh JD, Gribben J, Agrawal SG, Mattes FM. Treatment of respiratory syncytial virus infection in haemopoietic stem cell transplant recipients with aerosolized ribavirin and the humanized monoclonal antibody palivizumab: a single centre experience. <i>Br J Haematol</i>. 2009;146(5):574&#x2013;576. doi: 10.1111/j.1365-2141.2009.07763.x
</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2141.2009.07763.x</ArticleId><ArticleId IdType="pubmed">19538531</ArticleId></ArticleIdList></Reference><Reference><Citation>de Fontbrune FS, Robin M, Porcher R, et al. Palivizumab treatment of respiratory syncytial virus infection after allogeneic hematopoietic stem cell transplantation. <i>Clin Infect Dis</i>. 2007;45(8):1019&#x2013;1024. doi: 10.1086/521912
</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/521912</ArticleId><ArticleId IdType="pubmed">17879919</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu V, Dhillon GS, Weill D. A multi-drug regimen for respiratory syncytial virus and parainfluenza virus infections in adult lung and heart-lung transplant recipients. <i>Transpl Infect Dis</i>. 2010;12(1):38&#x2013;44. doi: 10.1111/j.1399-3062.2009.00453.x
</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1399-3062.2009.00453.x</ArticleId><ArticleId IdType="pubmed">19761558</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghosh S, Champlin RE, Englund J, et al. Respiratory syncytial virus upper respiratory tract illnesses in adult blood and marrow transplant recipients: combination therapy with aerosolized ribavirin and intravenous immunoglobulin. <i>Bone Marrow Transplant</i>. 2000;25(7):751&#x2013;755. doi: 10.1038/sj.bmt.1702228
</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.bmt.1702228</ArticleId><ArticleId IdType="pubmed">10745261</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarthy AJ, Kingman HM, Kelly C, et al. The outcome of 26 patients with respiratory syncytial virus infection following allogeneic stem cell transplantation. <i>Bone Marrow Transplant</i>. 1999;24(12):1315&#x2013;1322. doi: 10.1038/sj.bmt.1702078
</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.bmt.1702078</ArticleId><ArticleId IdType="pubmed">10627641</ArticleId></ArticleIdList></Reference><Reference><Citation>Akhmedov M, Wais V, Sala E, et al. Respiratory syncytial virus and human metapneumovirus after allogeneic hematopoietic stem cell transplantation: impact of the immunodeficiency scoring index, viral load, and ribavirin treatment on the outcomes. <i>Transpl Infect Dis</i>. 2020;22(4):e13276. doi: 10.1111/tid.13276
</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/tid.13276</ArticleId><ArticleId IdType="pubmed">32162389</ArticleId></ArticleIdList></Reference><Reference><Citation>Tejada S, Martinez-Reviejo R, Karakoc HN, Pe&#xf1;a-L&#xf3;pez Y, Manuel O, Rello J. Ribavirin for treatment of subjects with respiratory syncytial virus-related infection: a systematic review and meta-analysis. <i>Adv Ther</i>. 2022;39(9):4037&#x2013;4051. doi: 10.1007/s12325-022-02256-5
</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12325-022-02256-5</ArticleId><ArticleId IdType="pubmed">35876973</ArticleId></ArticleIdList></Reference><Reference><Citation>Wongsurakiat P, Sunhapanit S, Muangman N. Respiratory syncytial virus-associated acute respiratory illness in adult non-immunocompromised patients: outcomes, determinants of outcomes, and the effect of oral ribavirin treatment. <i>Influenza Other Respi Viruses</i>. 2022;16(4):767&#x2013;779. doi: 10.1111/irv.12971</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/irv.12971</ArticleId><ArticleId IdType="pmc">PMC9178057</ArticleId><ArticleId IdType="pubmed">35150065</ArticleId></ArticleIdList></Reference><Reference><Citation>Labay CE, Harris JE, Saille JC, Lin J. Treatment of respiratory syncytial virus with palivizumab in an adult liver transplant recipient: a case report. <i>J Emerg Crit Care Med</i>. 2023;7:1. doi: 10.21037/jeccm-22-59</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/jeccm-22-59</ArticleId></ArticleIdList></Reference><Reference><Citation>Banna GL, Aversa SML, Cattelan AM, Crivellari G, Monfardini S. Respiratory syncytial virus-related pneumonia after stem cell transplantation successfully treated with palivizumab and steroid therapy. <i>Scand J Infect Dis</i>. 2004;36(2):155&#x2013;157. doi: 10.1080/00365540410019282
</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00365540410019282</ArticleId><ArticleId IdType="pubmed">15061675</ArticleId></ArticleIdList></Reference><Reference><Citation>Grodin JL, Wu KS, Kitchell EE. Respiratory syncytial virus pneumonia treated with lower-dose palivizumab in a heart transplant recipient. <i>Case Rep Cardiol</i>. 2012;2012:723407. doi: 10.1155/2012/723407
</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2012/723407</ArticleId><ArticleId IdType="pmc">PMC4008357</ArticleId><ArticleId IdType="pubmed">24826271</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>